The tweet was deleted by the author.
But we saved everything 🙂.
Arvinas announced plans to share new data in an oral presentation on its PROTAC LRRK2 degrader at an upcoming movement disorder event.
The company did not provide specific details in the tweet but indicated that more information would be disclosed during the oral presentation. The development relates to therapies for conditions such as Parkinson disease, emphasizing Arvinas ongoing commitment to advancing its pipeline of targeted protein degraders.
View post on X Loading...
Arvinas has recently expanded its research into targeted protein degradation. The company started dosing in a Phase 1/2 clinical trial of its HPK1 PROTAC degrader, marking an early step in developing new therapies for challenging diseases, according to a previous report here. The ongoing studies highlight Arvinas’s efforts to advance its clinical pipeline.